[CDK4, a specific target in the treatment of lung adenocarcinomas mutated for KRAS].

Authors :: Dubus P
Source :: Medecine sciences : M/S [Med Sci (Paris)] 2010 Dec; Vol. 26 (12), pp. 1023-5.
Publication Year :: 2010

Subjects :: Adenocarcinoma drug therapy
Adenocarcinoma genetics
Adenoma drug therapy
Adenoma genetics
Adenoma therapy
Animals
Cellular Senescence drug effects
Cellular Senescence genetics
Cyclin-Dependent Kinase 4 physiology
Drug Screening Assays, Antitumor
Gene Expression Regulation, Neoplastic drug effects
Humans
Lung Neoplasms drug therapy
Lung Neoplasms genetics
Mice
Mutation
Piperazines therapeutic use
Proto-Oncogene Proteins
Proto-Oncogene Proteins p21(ras) genetics
Proto-Oncogene Proteins p21(ras) physiology
Pyridines therapeutic use
RNA Interference
ras Proteins
Adenocarcinoma therapy
Antineoplastic Agents therapeutic use
Cyclin-Dependent Kinase 4 antagonists & inhibitors
Genes, ras
Lung Neoplasms therapy
Molecular Targeted Therapy
Protein Kinase Inhibitors therapeutic use
RNA, Small Interfering therapeutic use

Full Text Access

Tools